GLP1R and heart failure: In the matched cohort comparing GLP-1 RAs with sulfonylureas, GLP-1 RA treatment was significantly associated with reduced risks of MACE (aHR 0.66, 95% CI 0.58–0.75), hospitalization for coronary artery disease (aHR 0.74, 95% CI 0.61–0.88), stroke (aHR 0.64, 95% CI 0.54–0.76), heart failure (aHR 0.54, 95% CI 0.42–0.70), major microvascular complications (aHR 0.68, 95% CI 0.56–0.82), end-stage kidney disease (aHR 0.39, 95% CI 0.27–0.57), leg amputation (aHR 0.29, 95% CI 0.09–0.91), and all-cause mortality (aHR 0.46, 95% CI 0.39–0.54).